Altered methotrexate clearance in the treatment of CNS lymphoma with concurrent use of nitrofurantoin for a urinary tract infection

Jasmine L. Gowarty, Ina J. Patel, Jon D. Herrington

Research output: Contribution to journalArticlepeer-review

Abstract

Methotrexate is a widely used chemotherapy agent with a propensity for drug interactions placing the patient at risk for toxicities. There are several modes for altering methotrexate clearance including concomitant drugs leading to toxic effects on the kidneys, medications producing an acidic urine pH, and agents interfering with methotrexate transporters including the organic anion transporter and breast cancer resistance protein efflux pump. We report a case of a patient with central nervous system non-Hodgkin's lymphoma receiving high-dose methotrexate and being concomitantly treated for a urinary tract infection with nitrofurantoin. Subsequently, her initial methotrexate clearance was altered by the introduction of nitrofurantoin and returned to baseline when her nitrofurantoin was discontinued. This is the first case report describing the altered methotrexate clearance from concurrent administration of methotrexate and nitrofurantoin.

Original languageEnglish (US)
Pages (from-to)1794-1797
Number of pages4
JournalJournal of Oncology Pharmacy Practice
Volume25
Issue number7
DOIs
StatePublished - Oct 1 2019
Externally publishedYes

Keywords

  • breast cancer resistance protein
  • Methotrexate
  • nitrofurantoin
  • organic anion transporter
  • urinary pH

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Altered methotrexate clearance in the treatment of CNS lymphoma with concurrent use of nitrofurantoin for a urinary tract infection'. Together they form a unique fingerprint.

Cite this